Rexahn Pharmaceuticals Inc. | |
Stock Exchange | NYSE |
EPS |
$0.35 |
Market Cap |
$53.34 M |
Shares Outstanding |
31.75 M |
Public Float |
31.01 M |
Address |
15245 Shady Grove Road Rockville Maryland 20850 United States |
Employees | - |
Website | http://www.rexahn.com |
Updated | 09/14/2018 |
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; RX-5902 or Supinoxin for metastatic triple negative breast cancer; and RX-0201 or Archexin for renal cell carcinoma, glioblastoma, ovarian, stomach, and pancreatic cancer. It also develops nano-based drug delivery systems. |